Educational content only. Not medical advice. Consult a qualified physician.
Pentosan Polysulfate Sodium peptide
RecoveryFDA-approved (Elmiron) for interstitial cystitis. Injectable use for osteoarthritis is common in veterinary medicine. Human injectable use for joint conditions is off-label.

PPS

Pentosan Polysulfate Sodium

Pentosan Polysulfate Sodium (PPS) is a semi-synthetic polysulfated xylan derived from beechwood hemicellulose. While technically a polysaccharide rather than a peptide, it is often discussed alongside peptide therapies for joint and tissue health. It is FDA-approved as Elmiron for interstitial cystitis and has been used in veterinary medicine for osteoarthritis for decades.
Reported Benefits

Potential Benefits

  • FDA-approved for interstitial cystitis/painful bladder syndrome (Elmiron)
  • Extensive veterinary use for osteoarthritis in horses and dogs with positive outcomes
  • Research suggests glycosaminoglycan-restoring properties in cartilage
  • May support joint health through anti-inflammatory and cartilage-protective mechanisms
  • Studies indicate potential fibrinolytic and anti-thrombotic properties
Research Dosing

Recommended Starting Dose

Oral: 100 mg three times daily (FDA-approved dose). Injectable: 2-3 mg/kg subcutaneously (veterinary-derived protocol)

Based on published research protocols. Not a prescription.

Dosing Protocol

Oral (FDA-approved for IC): 100 mg three times daily. Response is typically assessed after 3-6 months. Injectable protocols (adapted from veterinary use): 2-3 mg/kg subcutaneously once or twice weekly for 4-6 weeks, then monthly maintenance. Regular ophthalmologic monitoring is recommended with chronic use due to maculopathy risk.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

For interstitial cystitis, the FDA label notes that pain relief may take 3-6 months. Joint-related benefits in veterinary use are typically observed over 4-8 weeks of injectable treatment.

Regulatory

Research Status

FDA-approved (Elmiron) for interstitial cystitis. Injectable use for osteoarthritis is common in veterinary medicine. Human injectable use for joint conditions is off-label.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Retinal pigmentary maculopathy associated with long-term oral use (important FDA warning)
  • GI upset (nausea, diarrhea) with oral administration
  • Headache
  • Hair loss (reversible, reported in some patients)
  • Bruising due to mild anticoagulant effects
  • Injection site reactions with subcutaneous/IM administration
  • Regular eye examinations recommended with long-term use
Related Research

More in Recovery

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.